ArticleMolecular and clinical oncology2025
Detection of
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical value of combinedOncology reviews · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) is the most common malignant tumor globally, and lung adenocarcinoma (LUAD) represents the most common pathologic subtype. The DNA methylation of Short Stature Homeobox 2 (SHOX2) and Ras Association Domain Family 1 Isoform A (RASSF1A) showed the potential of diagnosing LC. With the aim of investigating the diagnostic value of SHOX2 and RASSF1A methylation in early-stage LUAD, 50 lung tissue specimens from patients suffering from early-stage LUAD were analyzed, including 25 tumor tissue specimens and 25 paired non-tumor lung tissue specimens. The methylation status of SHOX2 and RASSF1A was assessed by using methylation-specific PCR. The results showed significantly elevated methylation status of SHOX2 and RASSF1A in tumor tissues compared with non-tumor tissues. The sensitivity and specificity of SHOX2 methylation were 76.0 and 88.0%, respectively. However, the sensitivity of RASSF1A methylation was only 32.0%, with a specificity of 96.0%. Furthermore, the sensitivity and specificity of SHOX2 and RASSF1A combined methylation were 80.0 and 84.0%, respectively. No significant correlation was observed between the methylation of SHOX2/RASSF1A and clinicopathological characteristics, regardless of sex, age, tumor differentiation degree, TNM stage, or nodal status. These findings suggest that the combined detection of SHOX2 and RASSF1A methylation has a potential diagnostic value for early-stage LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.